HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

Jessica N. McAlpine, Kimberly C. Wiegand, Russell S Vang, Brigitte Maria Ronnett, Anna Adamiak, Martin Köbel, Steve E. Kalloger, Kenneth D. Swenerton, David G. Huntsman, C. Blake Gilks, Dianne M. Miller

Research output: Contribution to journalArticle

Abstract

Background: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.Methods: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)). Five cases with documented recurrence and with tissue from the recurrence available for testing were analyzed to determine whether HER2 amplification status changed over time. Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.Results: Amplification of HER2 was observed in 6/33 (18.2%) mucinous carcinomas and 3/16 (18.8%) BOT. HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence. The prospectively identified recurrent mucinous carcinomas showed overexpression and amplification of HER2; one patient's tumor responded dramatically to trastuzumab in combination with conventional chemotherapy, while another patient experienced an isolated central nervous system recurrence after trastuzumab therapy.Conclusion: HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33, 18.2%), although not of prognostic significance. Trastuzumab therapy is a treatment option for patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.

Original languageEnglish (US)
Article number433
JournalBMC Cancer
Volume9
DOIs
StatePublished - Dec 10 2009

Fingerprint

Mucinous Adenocarcinoma
Recurrence
Therapeutics
Neoplasms
Molecular Targeted Therapy
Drug Therapy
Trastuzumab
Carboplatin
Paclitaxel
Ovarian Neoplasms
Central Nervous System

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. / McAlpine, Jessica N.; Wiegand, Kimberly C.; Vang, Russell S; Ronnett, Brigitte Maria; Adamiak, Anna; Köbel, Martin; Kalloger, Steve E.; Swenerton, Kenneth D.; Huntsman, David G.; Blake Gilks, C.; Miller, Dianne M.

In: BMC Cancer, Vol. 9, 433, 10.12.2009.

Research output: Contribution to journalArticle

McAlpine, JN, Wiegand, KC, Vang, RS, Ronnett, BM, Adamiak, A, Köbel, M, Kalloger, SE, Swenerton, KD, Huntsman, DG, Blake Gilks, C & Miller, DM 2009, 'HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy', BMC Cancer, vol. 9, 433. https://doi.org/10.1186/1471-2407-9-433
McAlpine, Jessica N. ; Wiegand, Kimberly C. ; Vang, Russell S ; Ronnett, Brigitte Maria ; Adamiak, Anna ; Köbel, Martin ; Kalloger, Steve E. ; Swenerton, Kenneth D. ; Huntsman, David G. ; Blake Gilks, C. ; Miller, Dianne M. / HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. In: BMC Cancer. 2009 ; Vol. 9.
@article{bfeb276b90004570ba920d2537d2861d,
title = "HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy",
abstract = "Background: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.Methods: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)). Five cases with documented recurrence and with tissue from the recurrence available for testing were analyzed to determine whether HER2 amplification status changed over time. Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.Results: Amplification of HER2 was observed in 6/33 (18.2{\%}) mucinous carcinomas and 3/16 (18.8{\%}) BOT. HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence. The prospectively identified recurrent mucinous carcinomas showed overexpression and amplification of HER2; one patient's tumor responded dramatically to trastuzumab in combination with conventional chemotherapy, while another patient experienced an isolated central nervous system recurrence after trastuzumab therapy.Conclusion: HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33, 18.2{\%}), although not of prognostic significance. Trastuzumab therapy is a treatment option for patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.",
author = "McAlpine, {Jessica N.} and Wiegand, {Kimberly C.} and Vang, {Russell S} and Ronnett, {Brigitte Maria} and Anna Adamiak and Martin K{\"o}bel and Kalloger, {Steve E.} and Swenerton, {Kenneth D.} and Huntsman, {David G.} and {Blake Gilks}, C. and Miller, {Dianne M.}",
year = "2009",
month = "12",
day = "10",
doi = "10.1186/1471-2407-9-433",
language = "English (US)",
volume = "9",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

AU - McAlpine, Jessica N.

AU - Wiegand, Kimberly C.

AU - Vang, Russell S

AU - Ronnett, Brigitte Maria

AU - Adamiak, Anna

AU - Köbel, Martin

AU - Kalloger, Steve E.

AU - Swenerton, Kenneth D.

AU - Huntsman, David G.

AU - Blake Gilks, C.

AU - Miller, Dianne M.

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Background: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.Methods: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)). Five cases with documented recurrence and with tissue from the recurrence available for testing were analyzed to determine whether HER2 amplification status changed over time. Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.Results: Amplification of HER2 was observed in 6/33 (18.2%) mucinous carcinomas and 3/16 (18.8%) BOT. HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence. The prospectively identified recurrent mucinous carcinomas showed overexpression and amplification of HER2; one patient's tumor responded dramatically to trastuzumab in combination with conventional chemotherapy, while another patient experienced an isolated central nervous system recurrence after trastuzumab therapy.Conclusion: HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33, 18.2%), although not of prognostic significance. Trastuzumab therapy is a treatment option for patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.

AB - Background: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovarian cancer.Methods: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)). Five cases with documented recurrence and with tissue from the recurrence available for testing were analyzed to determine whether HER2 amplification status changed over time. Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.Results: Amplification of HER2 was observed in 6/33 (18.2%) mucinous carcinomas and 3/16 (18.8%) BOT. HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence. The prospectively identified recurrent mucinous carcinomas showed overexpression and amplification of HER2; one patient's tumor responded dramatically to trastuzumab in combination with conventional chemotherapy, while another patient experienced an isolated central nervous system recurrence after trastuzumab therapy.Conclusion: HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33, 18.2%), although not of prognostic significance. Trastuzumab therapy is a treatment option for patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.

UR - http://www.scopus.com/inward/record.url?scp=74049094790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049094790&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-9-433

DO - 10.1186/1471-2407-9-433

M3 - Article

C2 - 20003286

AN - SCOPUS:74049094790

VL - 9

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 433

ER -